Benefits of PTX: Insights from the TRUE-PTX Study

Watch as vascular specialist Marianne Brodmann, MD, of the University of Graz in Austria, shares key insights from her presentation at ISET 2026, “Benefits of PTX: Insights from the TRUE-PTX Study”. Dr. Brodmann reviews the study, which compared paclitaxel (PTX) drug-eluting and bare device treatment for peripheral arterial disease (PAD) using real-world data design. She highlights how the data further define the role of PTX drug-eluting devices in contemporary peripheral vascular interventions, as well as the safety and efficacy of PTX and how the study results can help inform treatment decisions and optimize outcomes for patients with PAD.